Entering text into the input field will update the search result below

FDA clears two new indications for Novartis' Cosentyx

Jan. 16, 2016 2:21 PM ETNovartis AG (NVS) StockNVSBy: Douglas W. House, SA News Editor
  • The FDA approves Novartis' (NYSE:NVS) IL-17A inhibitor, Cosentyx (secukinumab), for the treatment of adults with active ankylosing spondylitis and active psoriatic arthritis, both life-long painful and debilitating inflammatory diseases that affect the joints and/or spine.
  • The European Commission approved the two new indications in November.
  • In January 2015, Cosentyx was cleared in the U.S. and EU for the treatment of adults with moderate-to-severe plaque psoriasis.
  • Cosentyx is one of the company's anticipated blockbusters that is expected to generate peak sales of $1B+. Through Q3, it has posted $140M in sales.

This was corrected on 02/04/2019 at 10:51 PM. The two new indications were cleared in Europe in November.

Recommended For You

More Trending News

About NVS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVS--
Novartis AG